| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5461 | 2010 |
| Isolation of rare circulating tumour cells in cancer patients by microchip technology S Nagrath, LV Sequist, S Maheswaran, DW Bell, D Irimia, L Ulkus, ... Nature 450 (7173), 1235-1239, 2007 | 4468 | 2007 |
| Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations LV Sequist, JCH Yang, N Yamamoto, K O'Byrne, V Hirsh, T Mok, ... Journal of clinical oncology 31 (27), 3327-3334, 2013 | 3791 | 2013 |
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors LV Sequist, BA Waltman, D Dias-Santagata, S Digumarthy, AB Turke, ... Science translational medicine 3 (75), 75ra26-75ra26, 2011 | 3734 | 2011 |
| Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition M Yu, A Bardia, BS Wittner, SL Stott, ME Smas, DT Ting, SJ Isakoff, ... science 339 (6119), 580-584, 2013 | 2714 | 2013 |
| Detection of Mutations in EGFR in Circulating Lung-Cancer Cells S Maheswaran, LV Sequist, S Nagrath, L Ulkus, B Brannigan, CV Collura, ... New England Journal of Medicine 359 (4), 366-377, 2008 | 2148 | 2008 |
| Isolation of circulating tumor cells using a microvortex-generating herringbone-chip SL Stott, CH Hsu, DI Tsukrov, M Yu, DT Miyamoto, BA Waltman, ... Proceedings of the National Academy of Sciences 107 (43), 18392-18397, 2010 | 1989 | 2010 |
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ... Jama 311 (19), 1998-2006, 2014 | 1830 | 2014 |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised … JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ... The lancet oncology 16 (2), 141-151, 2015 | 1795 | 2015 |
| Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study CJ Langer, SM Gadgeel, H Borghaei, VA Papadimitrakopoulou, A Patnaik, ... The lancet oncology 17 (11), 1497-1508, 2016 | 1506 | 2016 |
| Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ... Science translational medicine 4 (120), 120ra17-120ra17, 2012 | 1486 | 2012 |
| Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ... Journal of clinical oncology 33 (18), 2004-2012, 2015 | 1318 | 2015 |
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ... Cancer cell 17 (1), 77-88, 2010 | 1245 | 2010 |
| Inertial focusing for tumor antigen–dependent and–independent sorting of rare circulating tumor cells E Ozkumur, AM Shah, JC Ciciliano, BL Emmink, DT Miyamoto, E Brachtel, ... Science translational medicine 5 (179), 179ra47-179ra47, 2013 | 1209 | 2013 |
| EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective … JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ... Clinical cancer research 22 (18), 4585-4593, 2016 | 1166 | 2016 |
| Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016 | 1153 | 2016 |
| First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations LV Sequist, RG Martins, D Spigel, SM Grunberg, A Spira, PA Janne, ... Journal of clinical oncology 26 (15), 2442-2449, 2008 | 1050 | 2008 |
| Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 … JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ... The lancet oncology 16 (7), 830-838, 2015 | 1018 | 2015 |
| Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ... Nature medicine 22 (3), 262-269, 2016 | 965 | 2016 |
| Acquired resistance to TKIs in solid tumours: learning from lung cancer DR Camidge, W Pao, LV Sequist Nature reviews Clinical oncology 11 (8), 473-481, 2014 | 929 | 2014 |
